greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2024

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2024: revenue JPY 4,264 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2024 it reported revenue of JPY 4,264 billion ($29.5 billion at the year's average rate), up 5.9% on the year before. Its profit attributable to shareholders was JPY 144 billion, down 54.6%, and diluted earnings per share JPY 91.16.

Revenue
JPY 4,264 billion
+5.9% on the year
FY2017FY2024
Operating margin
5.0%
12.2% a year earlier
FY2017FY2024
Net income
JPY 144 billion
-54.6% on the year
FY2017FY2024
Diluted EPS
JPY 91.16
-54.9% on the year
FY2017FY2024

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2023Mar 2024
Revenue4,0274,264
Cost of sales1,2441,427
Research and development633730
Operating profit491214
Finance costs170220
Profit before tax37552.8
Income tax58.1-91.4
Profit for the year317144
Profit attributable to shareholders317144
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2023Mar 2024
Diluted EPS201.9491.16
Basic EPS204.2992.09
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2023Mar 2024
Cash from operations977716
Purchase of property, plant and equipment141175
Free cash flow836541
Cash from investing-607-464
Cash from financing-709-354
Depreciation and amortisation664728
Buybacks26.92.3
Dividends paid279287
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2023Mar 2024
Funded by
Equity attributable to shareholders6,3547,273
Non-controlling interests0.50.7
Borrowings, as filed4,3824,844
Lease liabilities479620
Other liabilities2,7412,371
Total equity and liabilities13,95815,109
Owned
Property, plant and equipment1,6911,990
Goodwill4,7915,410
Other intangible assets4,2704,275
Cash and cash equivalents534458
Trade and other receivables649668
Inventories9861,210
Other assets1,0371,098
Total assets13,95815,109
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2023Mar 2024
Operating margin12.2%5.0%
Net margin7.9%3.4%
Free cash flow margin20.8%12.7%
Return on year-end equity5.0%2.0%
Effective tax rate15.5%-173.1%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2024, filed 17 June 2026: the filing. The figures are in yen as filed.